论文部分内容阅读
观察分析口服ＣｓＡ治疗２６例小儿难治性肾病综合征（系膜增殖性肾小球肾炎１５例、微小病变８例、系膜增殖并局灶性硬化２例）的疗效。在强的松减量的过程中，给以ＣｓＡ口服，按５ｍｇ／（ｋｇ·ｄ），疗程３～６个月，并监测血浓度。２６例患儿经治疗后，住院期间（１个月）尿蛋白转阴者２１例（８０．７７％），尿蛋白减少者３例（１１．５４％），无效者２例（７．６９％），总有效率达９２．３１％（ｔ＝５．２３４，Ｐ＜０．０１），显效时间为７～２３天，平均１３天。ＣｓＡ是替代激素治疗该类病人的较好方法之一，尤其是临床表现为激素依赖及Ｃａｓｈｉｎｇ征明显，且病理类型为ＭｓＰＧＮ和ＭＣＮＳ者疗效好，而ＦＳＧＳ者疗效较差
Observation and analysis of oral CsA treatment of 26 cases of pediatric refractory nephrotic syndrome (mesangial proliferative glomerulonephritis in 15 cases, 8 cases of minimal change, mesangial proliferation and focal sclerosis in 2 cases). In the course of prednisone reduction, given CsA orally, according to 5mg / (kg · d), treatment of 3 to 6 months, and blood concentration monitoring. Twenty-six infants had urinary protein negative in 21 (80.77%), urinary protein reduced in 3 (11.54%) and ineffective in 2 (7.69 %), The total effective rate was 92.31% (t = 5.234, P <0.01), effective time was 7 to 23 days, an average of 13 days. CsA is one of the better alternatives to hormone treatment of such patients, especially clinical manifestations of hormone dependent and Cashing sign was obvious, and the pathological type of MsPGN and MCNS were effective, and FSGS were less effective